Novo Nordisk A/S: Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders

Bagsværd, Denmark and Watertown, Mass, US, 01 September 2022 - Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have entered into a definitive agreement under

Related Keywords

Germany ,United States ,Denmark ,United Kingdom ,Washington ,Italy ,France ,Spain ,Adam Bero ,Greg Klassen Joele Frank ,Ludovic Helfgott ,Ambre Brown Morley ,Frankd Lee ,Daniel Muusmann Bohsen ,Natalia Salomao Abrahao ,David Heiberg Landsted ,Jamie Moser Joele Frank ,Wilkinson Brimmer Katcher ,Jacob Martin Wiborg ,Novo Nordisk ,Holdings Inc ,Linkedin ,Twitter ,Gdev Inc ,Nasdaq ,Forma Therapeutics Holdings Inc ,Facebook ,Drug Administration ,Davis Polk Wardwell ,European Commission ,Centerview Partners ,Exchange Commission ,Youtube ,Moelis Company United Kingdom ,Novo Nordisk Investor Relations Department ,Goodwin Procter ,Forma Investor Relations Department ,Forma Therapeutics ,Rare Disease ,Forma Therapeutic ,Forma Therapeutics Board ,Company United Kingdom ,Davis Polk ,Fast Track ,Rare Pediatric Disease ,Orphan Drug ,Orphan Medicinal Products ,European Medicines Agency ,Salomao Abrahao ,Joele Frank ,Brimmer Katcher ,Joseph Root ,Kendell Investor Relations ,Forma Therapeutics Holdings ,Tender Offer Statement ,Recommendation Statement ,Investor Relations Department ,Novo ,Nordisk ,Cquire ,Norma ,Herapeutics ,Xpand ,Presence ,Pickle ,Fell ,Disease ,Mare ,Flood ,Disorders ,